Compare Stocks: SVRA, NERV, and CRVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$9.52	$12.83	$6.39 ▼ $26.95	$800.82M	1.44	1.12 million shs	1.04 million shs
NERV Minerva Neurosciences	$2.35	$3.91	$2.28 ▼ $12.46	$112.21M	-0.1	118,249 shs	85,598 shs
SVRA Savara	$4.45	$5.23	$3.49 ▼ $7.01	$914.30M	0.2	2.59 million shs	2.23 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	-9.51%	-24.20%	-32.48%	+35.23%
NERV Minerva Neurosciences	0.00%	-26.10%	-35.79%	-46.22%	-5.62%
SVRA Savara	0.00%	-9.55%	-17.13%	-18.94%	+23.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$9.52	$12.83	$6.39 ▼ $26.95	$800.82M	1.44	1.12 million shs	1.04 million shs
NERV Minerva Neurosciences	$2.35	$3.91	$2.28 ▼ $12.46	$112.21M	-0.1	118,249 shs	85,598 shs
SVRA Savara	$4.45	$5.23	$3.49 ▼ $7.01	$914.30M	0.2	2.59 million shs	2.23 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	-9.51%	-24.20%	-32.48%	+35.23%
NERV Minerva Neurosciences	0.00%	-26.10%	-35.79%	-46.22%	-5.62%
SVRA Savara	0.00%	-9.55%	-17.13%	-18.94%	+23.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	250.14% Upside
NERV Minerva Neurosciences	2.00	Hold	$10.33	339.72% Upside
SVRA Savara	2.75	Moderate Buy	$10.25	130.34% Upside

Current Analyst Ratings Breakdown

Latest SVRA, NERV, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	SVRA Savara	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/9/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/7/2026	SVRA Savara	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$10.00
10/7/2026	SVRA Savara	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/7/2026	SVRA Savara	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$12.00
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
7/30/2026	CRVS Corvus Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
7/28/2026	CRVS Corvus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	75.11	$0.73 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest SVRA, NERV, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	SVRA Savara	-$0.1633	N/A	N/A	N/A	$0.50 million	N/A
11/4/2026	Q3 2026	NERV Minerva Neurosciences	-$0.14	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	CRVS Corvus Pharmaceuticals	-$0.1921	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
NERV Minerva Neurosciences	N/A	20.15	20.14
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
NERV Minerva Neurosciences	34.56%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	19.70%
NERV Minerva Neurosciences	1.70%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Not Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

SVRA, NERV, and CRVS Headlines

Recent News About These Companies

Savara schedules CHEST 2026 presentations for Savara stock

October 18 at 2:22 PM | ad-hoc-news.deA

Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?

October 13, 2026 | finance.yahoo.com

Savara Inc. (SVRA) - What Are Analysts Thinking About This Stock?

October 13, 2026 | americanbankingnews.com

Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to Analysts

October 13, 2026 | marketbeat.com

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis ...

October 12, 2026 | joplinglobe.comJ

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

October 12, 2026 | businesswire.com

JPMorgan starts Savara coverage with USD 12 target for Savara stock

October 8, 2026 | ad-hoc-news.deA

Savara stock gets USD 12 JPMorgan target before FDA date

October 8, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Now Covered by Analysts at JPMorgan Chase & Co.

October 8, 2026 | americanbankingnews.com

Savara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?

October 7, 2026 | marketbeat.com

JPMorgan Initiates Savara at Overweight With $12 Price Target

October 7, 2026 | marketscreener.comM

Savara (SVRA) Reiterated at Market Outperform by Citizens on Molbreevi Optimism

October 7, 2026 | streetinsider.com

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at JPMorgan Chase & Co.

October 7, 2026 | marketbeat.com

Savara stock fell 4.66 percent ahead of the November FDA decision

October 4, 2026 | ad-hoc-news.deA

Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen

October 4, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Stock Falls 5.4% - Here's Why

October 2, 2026 | marketbeat.com

Bank of America Corp DE Buys 520,356 Shares of Savara Inc. $SVRA

September 30, 2026 | marketbeat.com

Savara (NASDAQ:SVRA) Raised to Hold at Wall Street Zen

September 26, 2026 | marketbeat.com

Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?

September 24, 2026 | rttnews.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, NERV, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$9.52 0.00 (0.00%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$9.53 +0.01 (+0.11%)

As of 10/16/2026 07:58 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Minerva Neurosciences NASDAQ:NERV

$2.35 0.00 (0.00%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.36 +0.01 (+0.43%)

As of 10/16/2026 07:30 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Savara NASDAQ:SVRA

$4.45 0.00 (0.00%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$4.46 +0.00 (+0.11%)

As of 10/16/2026 07:55 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, NERV, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, NERV, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, NERV, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, NERV, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Minerva Neurosciences NASDAQ:NERV

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVRA, NERV, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVRA, NERV, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVRA, NERV, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA, NERV, and CRVS Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

Minerva Neurosciences NASDAQ:NERV

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools